Additional Developments

Additional Developments

  • Palade BioTech develops “PaLAD (Palade Long-Acting Drug)” technology for drugs to act very long after administration.
  • Using our oncolytic ADC drug technology, Palade BioTech develop “molecular precision scalpel” by targeted killing and removing the invisible, remaining cancer cells after cancer surgery.
  • Palade BioTech develops GPCR-target drugs in addition to the GPCR-target tumor microenvironment modulator drugs using our MoSTT-CelSuR platform technology. We focus on GPCR-target drugs for metabolic diseases and anti-aging.

GLP-1 R target obesity drugs

  • GLP-1 R target peptide obesity drugs :

    Gigantic global markets

  • 100 billion global market in 2030 is estimated, attracting drug developeres to develop better obesity drugs

X target heart failure drugs

  • X target recovery of heart failure is well-established, attracting drug developers to develop better heart failure drugs

Y target muscle loss drugs

  • Y target recovery of muscle loss (Sarcopenia) is well-established, attracting drug developers